News By Tag Industry News News By Location Country(s) Industry News
| Estrogen Receptor Positive (ER+) Breast Cancer - Pipeline Insights, 2016DelveInsight, the leading market research and consulting company has added new report Estrogen Receptor Positive (ER+) Breast Cancer - Pipeline Insights, 2016 to its portfolio.
By: DelveInsight Business Reseacrh Estrogen Positive (ER+) Breast Cancer-Pipeline Insights, 2016 comprehensively includes: • In-depth analysis of the pipeline assets across this indication. • Insights on 40+ products with 30+ companies which are active in this field. • R&D activities and technologies used along with the pipeline molecules in development. • Information related to collaborations, in-licensing and out-licensing deals. • Stages of development of pipeline molecules. • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. • Highlights the discontinued and inactive projects in pipeline. Estrogen Receptor Positive (ER+) Breast Cancer - Pipeline Insights, 2016 Report envisage Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight's report on Estrogen Receptor Positive (ER+) Breast Cancer helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals. DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, visit https://www.delveinsight.com or email at info@delveInsight.com About Us: DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; End
Page Updated Last on: Jun 15, 2016
|
| ||||||||||||||||||||||||||||||||||||||||||||||||